PET scans show biomarkers could spare some breast cancer patients from chemotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy, according to a study led by researchers at the Johns Hopkins Kimmel Cancer Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login